CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale CHIEF ACCOUNTING OFFICER sold 20,000 shares at an average $101.38 ($2,027,646)
- S-3ASR Offering Registration Statement
- 144 Insider Sale of Securities
- 4 Planned sale EVP, Head of R&D sold 23,124 shares at an average $106.41 ($2,460,690)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 2,778 shares at $117.55 ($326,554)
- 4 Option exercise SVP, General Counsel and Sec. acquired 15,000 shares (option exercise)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Director sold 7,750 shares at an average $109.01 ($844,822)
- 4 Planned sale Director sold 2,777 shares at an average $109.55 ($304,232)
- 4 Planned sale SVP, General Counsel and Sec. sold 20,000 shares at an average $110.44 ($2,208,833)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CEO AND PRESIDENT sold 166,000 shares at an average $108.11 ($17,945,451)
Page 1 of 33 · 659 filings